Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open Label Trial in Treatment na�ve, HIV 1 Infected Subjects Who Will Receive TMC114/Rtv as a Monotherapy

NCT00513513 is registered in ClinicalTrials.gov with Tibotec Pharmaceuticals, Ireland as lead sponsor.

NCT NCT00513513
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00513513 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open Label Trial in Treatment na�ve, HIV 1 Infected Subjects Who Will Receive TMC114/Rtv as a Monotherapy
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Phase
Phase 2
Overall status
Terminated
Start date
September 30, 2006
Completion date
October 31, 2007
Enrollment
7 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections